Navigation Links
Aragon Pharmaceuticals Announces $8 Million Series A Financing
Date:5/20/2009

LA JOLLA, Calif., May 20 /PRNewswire/ -- Aragon Pharmaceuticals today announced it has raised $8 million in Series A financing led by The Column Group and OrbiMed Advisors. Funds from the Series A financing will be used to discover and develop new small molecule therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

Aragon Pharmaceuticals is a San Diego-based biopharmaceutical company built on the pioneering research of Charles Sawyers, M.D., an investigator at Memorial Sloan Kettering Cancer Center and the Howard Hughes Medical Institute, and Michael Jung, Ph.D., a professor at UCLA, who are founders of Aragon. Their recent discoveries show that the biology of hormone-resistant cancers can be overcome through the creation of a new class of nuclear receptor targeting drugs, thereby opening the door to a pipeline of new anti-endocrine therapies. This approach will produce drugs that are mechanistically distinct from existing therapies in the clinic and the current research pipeline.

Aragon is bringing together a proven team to drive the drug discovery programs. The Company is led by Richard A. Heyman, Ph.D., President and Head of Research and Development, who has worked in the nuclear receptor drug discovery field for 20 years and brought multiple compounds into the clinic and market. Aragon's Board of Directors includes Richard Heyman, Peter Svennilson, Founder and Managing Partner of The Column Group and Carl Gordon, founding General Partner of OrbiMed.

Rick Klausner, Aragon's Co-Chairman of the Scientific Advisory Board, Managing Partner at The Column Group, and former Director of the National Cancer Institute, stated that "30% of all cancers arise from hormone responsive tissues and hormonal therapy has been one of the bedrocks of cancer treatment. Unfortunately most of these tumors are or become resistant to available therapies. Breakthrough science has created the opportunity for Aragon to solve the problem of treatment resistance by creating a new approach to hormone receptor therapy."

"Aragon will build off the work of our founders and focus on the discovery and development of compounds that target the degradation of the androgen and estrogen receptor, to treat patients with hormone refractory disease," stated Dr. Richard Heyman. "The company has recruited an experienced drug discovery team and several world-renowned scientists to the Scientific Advisory Board to help guide the discovery and development of our research programs."

Peter Svennilson noted, "It is the caliber of the people behind Aragon and the tremendous potential that this approach has for treating hormone dependent cancers that excited us about funding this opportunity. The Aragon team is poised to generate a pipeline of novel cancer therapies and I look forward to working with Aragon to achieve their vision to effectively treat hormone refractory cancers."

For more information, please see:

http://www.aragonpharmaceuticals.com

or email:

info@aragonpharmaceuticals.com


'/>"/>
SOURCE Aragon Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
2. Paragon Medsystems Becomes California MedTech
3. Paragon Benefits, Inc. Selects North Star Health for Data Analysis and Cost Management Reporting
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
Breaking Medicine Technology: